Medicamen Biotech Limited

MEDICAMEQ

INE646B01010

Pharmaceuticals

Delayed Bombay S.E. Other stock markets 11:49:56 16/05/2024 am IST			5-day change	1st Jan Change
498 ^INR	+0.64%		-4.76%	-17.86%

12/02	Medicamen Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI
2023	Medicamen Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	CI

Medicamen Biotech Limited Recommends Final Dividend for the Financial Year 2021-22

May 25, 2022 at 04:23 pm IST

Medicamen Biotech Limited announced that at its board meeting held on May 25, 2022, recommended a final dividend at 10% on equity shares of INR 10 each that is INR 1 per equity share for the financial Year 2021-22.

Latest news about Medicamen Biotech Limited

Medicamen Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	12/02	CI
Medicamen Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	10/11	CI
Medicamen Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	08/23/08	CI
Medicamen Biotech Limited Recommends Final Dividend for Financial Year 2022-23	29/23/29	CI
Medicamen Biotech Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	29/23/29	CI
Medicamen Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	10/23/10	CI
Medicamen Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	11/22/11	CI
INDIA STOCKS-Indian shares seen opening higher as global equities attempt bounce	04/22/04	RE
Medicamen Biotech Forays into Domestic Indian Pharmaceutical Business	04/22/04	MT
Medicamen Biotech Forms New Unit	26/22/26	MT
Medicamen Biotech Ties Up with Danish Pharmaceutical Firm for Manufacturing of Drugs	12/22/12	MT
Medicamen Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	10/22/10	CI
Medicamen Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	25/22/25	CI
Medicamen Biotech Limited Recommends Final Dividend for the Financial Year 2021-22	25/22/25	CI
Medicamen Biotech Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021	08/22/08	CI
Promoter Group Narrows Stake in Medicamen Biotech	04/22/04	MT
Promoter Group Lowers Stake in Medicamen Biotech to 2.93%	10/21/10	MT
Medicamen Biotech's Consolidated Net Profit Climbs in Fiscal Q2	05/21/05	MT
Medicamen Biotech Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2021	03/21/03	CI
Medicamen Biotech Limited Reports Earnings Results for the First Quarter Ended June 30, 2021	13/21/13	CI
Medicamen Biotech Limited Recommends Final Dividend for the Fiscal Year 2021	26/21/26	CI
Medicamen Biotech Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2021	26/21/26	CI
Medicamen Biotech : Shivalik Rasayan Boosts Stake in Medicamen Biotech to 41.79%	24/21/24	MT
Medicamen Biotech : Promoter Shivalik Rasayan Lifts Stake in Medicamen Biotech to 41.55%	19/21/19	MT
Medicamen Biotech : Promoter Group Sheds Stake in Medicamen Biotech	18/21/18	MT

Chart Medicamen Biotech Limited

Duration

Period

More charts

Company Profile

Medicamen Biotech Limited is an India-based integrated pharmaceutical and life sciences solution provider company. The Company is engaged in manufacturing of diverse range of pharmaceutical products oral solids, oral liquids, ointment for non-oncology products range and also produces tablets, capsule/lyohilized/dry powder injections for oncology product range. It focuses on oncology therapeutics, and other generics. The Company manufactures a range of products, including tablets, capsules, liquid syrup, dry syrup, such as beta-lactum and non-beta lactum, and ointments. The Company primarily focuses on oncology therapeutics. It is also focused on other therapeutic areas, such as cardiology, central nervous system (CNS), diabetology and pain management. Its oncology products include Abiraterone acetate, Anastrozole, Bicalutamide, Bendmustine HCL, Bortezomib, Busulfan, Capecitabine, Cisplatin, Erlotinib HCL, Gefitinib, Imatinib mesylate, Lenalidomide, Letrozole, Melphalan, and Pazopanib.

Sector

Pharmaceuticals

Calendar

29/05/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
MEDICAMEN BIOTECH LIMITED	-17.86%	7.54Cr
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.28%	4.39TCr
OTSUKA HOLDINGS CO., LTD.	+24.47%	2.31TCr
SANDOZ GROUP AG	+19.22%	1.53TCr
CIPLA LIMITED	+12.87%	1.36TCr
ZYDUS LIFESCIENCES LIMITED	+44.67%	1.2TCr
ONO PHARMACEUTICAL CO., LTD.	-9.92%	699.72Cr
THE MEDICINES COMPANY	-0.05%	678.76Cr
STADA ARZNEIMITTEL	-8.87%	572.55Cr
ASPEN PHARMACARE HOLDINGS LIMITED	+13.07%	559.68Cr

Generic Pharmaceuticals